Published in Blood on April 26, 2010
Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). Oncology (Williston Park) (2011) 2.21
Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease. Blood (2011) 1.88
Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach. Blood (2013) 1.53
Second malignancies after multiple myeloma: from 1960s to 2010s. Blood (2012) 1.46
Obesity and the risk for a hematological malignancy: leukemia, lymphoma, or myeloma. Oncologist (2010) 1.22
Inherited genetic susceptibility to multiple myeloma. Leukemia (2013) 1.04
Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites. Leukemia (2011) 1.03
A prospective study of circulating adipokine levels and risk of multiple myeloma. Blood (2012) 0.97
Gender disparities in the tumor genetics and clinical outcome of multiple myeloma. Cancer Epidemiol Biomarkers Prev (2011) 0.97
Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease. Clin Cancer Res (2012) 0.96
Body size and multiple myeloma mortality: a pooled analysis of 20 prospective studies. Br J Haematol (2014) 0.95
Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma. N Engl J Med (2016) 0.89
Anthropometric, behavioral, and female reproductive factors and risk of multiple myeloma: a pooled analysis. Cancer Causes Control (2013) 0.88
Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey. Leukemia (2014) 0.88
Diet-induced obesity promotes a myeloma-like condition in vivo. Leukemia (2014) 0.87
Precursors to lymphoproliferative malignancies. Cancer Epidemiol Biomarkers Prev (2013) 0.84
Unusual case of simultaneous presentation of plasma cell myeloma, chronic myelogenous leukemia, and a jak2 positive myeloproliferative disorder. Case Rep Hematol (2014) 0.83
Racial differences in primary cytogenetic abnormalities in multiple myeloma: a multi-center study. Blood Cancer J (2015) 0.79
MGUS to myeloma: a mysterious gammopathy of underexplored significance. Blood (2016) 0.76
High prevalence of polyclonal hypergamma-globulinemia in adult males in Ghana, Africa. Am J Hematol (2011) 0.75
The White House crusade against ... MGUS? Blood (2010) 0.75
Obesity and the Transformation of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma: A Population-Based Cohort Study. J Natl Cancer Inst (2016) 0.75
Efficacy and Safety of Novel Agent-Based Therapies for Multiple Myeloma: A Meta-Analysis. Biomed Res Int (2016) 0.75
Lack of health maintenance examinations and risk in myeloma patients. Cancer Med (2016) 0.75
Five-Year Follow-up Study of Monoclonal Gammopathy of Undetermined Significance in a Korean Elderly Urban Cohort. Cancer Res Treat (2014) 0.75
Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet (2008) 20.62
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol (2003) 14.41
Multiple myeloma. N Engl J Med (2004) 10.81
Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med (2006) 7.24
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood (2009) 5.69
Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature (1988) 5.60
Southern community cohort study: establishing a cohort to investigate health disparities. J Natl Med Assoc (2005) 3.67
Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood (2005) 3.25
Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin Proc (2007) 2.91
Anthropometric characteristics and risk of multiple myeloma. Epidemiology (2005) 1.85
Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis. Leukemia (2009) 1.48
Mortality and social class in Sweden--exploring a new epidemiological tool. Scand J Soc Med (1989) 1.44
Increased incidence of monoclonal gammopathy of undetermined significance in blacks and its age-related differences with whites on the basis of a study of 397 men and one woman in a hospital setting. J Lab Clin Med (1990) 1.42
Increasing trends of multiple myeloma mortality in England and Wales; 1950-79: are the changes real? J Natl Cancer Inst (1982) 1.33
A case-control study of multiple myeloma nested in the American Cancer Society prospective study. Int J Cancer (1989) 1.28
Waldenström's macroglobulinemia: incidence patterns in the United States, 1988-1994. Cancer (1998) 1.27
Incidence of Waldenström's macroglobulinemia. Blood (1993) 1.27
Anthropometric characteristics and non-Hodgkin's lymphoma and multiple myeloma risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). Haematologica (2008) 1.16
Socioeconomic status and multiple myeloma among US blacks and whites. Am J Public Health (2000) 1.16
Monoclonal gammopathy of undetermined significance: genetic vs environmental etiologies. Mayo Clin Proc (2007) 1.14
Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden. Int J Cancer (2009) 1.12
Multiple myeloma cells are protected against dexamethasone-induced apoptosis by insulin-like growth factors. Br J Haematol (1997) 1.09
Association between insulin-like growth factor-I: insulin-like growth factor-binding protein-1 ratio and metabolic and anthropometric factors in men and women. Cancer Epidemiol Biomarkers Prev (2004) 1.04
Changes in mortality rates from multiple myeloma. N Engl J Med (1980) 0.83
Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med (2006) 0.81
A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet (2007) 22.96
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet (2007) 21.18
Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet (2008) 17.65
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med (2003) 16.11
Replicating genotype-phenotype associations. Nature (2007) 16.11
Improved survival in multiple myeloma and the impact of novel therapies. Blood (2007) 12.70
Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol (2011) 12.10
International staging system for multiple myeloma. J Clin Oncol (2005) 11.29
Multiple myeloma. N Engl J Med (2004) 10.81
Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc (2003) 9.96
A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med (2002) 8.63
Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. Nat Genet (2009) 8.44
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med (2007) 8.41
A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet (2009) 8.39
Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24
Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med (2006) 7.24
Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell (2007) 7.24
Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS (2006) 7.08
Prediction error estimation: a comparison of resampling methods. Bioinformatics (2005) 6.41
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 6.19
Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med (2007) 6.07
Multiple myeloma. Blood (2008) 5.88
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood (2005) 5.82
On criteria for evaluating models of absolute risk. Biostatistics (2005) 5.71
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood (2009) 5.69
A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. Am J Hum Genet (2009) 5.62
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet (2013) 5.58
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med (2014) 5.08
Spectrum of cancer risk among US solid organ transplant recipients. JAMA (2011) 4.99
A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet (2010) 4.89
Quality control and quality assurance in genotypic data for genome-wide association studies. Genet Epidemiol (2010) 4.83
Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet (2010) 4.75
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst (2011) 4.69
Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood (2003) 4.67
Merging and emerging cohorts: not worth the wait. Nature (2007) 4.66
Meta-analysis of genome-wide association studies identifies eight new loci for type 2 diabetes in east Asians. Nat Genet (2011) 4.50
Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood (2005) 4.48
Pathway analysis by adaptive combination of P-values. Genet Epidemiol (2009) 4.48
Clonal competition with alternating dominance in multiple myeloma. Blood (2012) 4.39
POEMS syndrome: definitions and long-term outcome. Blood (2002) 4.35
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Age at cancer diagnosis among persons with AIDS in the United States. Ann Intern Med (2010) 4.30
B-cell clones as early markers for chronic lymphocytic leukemia. N Engl J Med (2009) 4.27
Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem (2002) 4.24
Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. Nat Genet (2014) 4.13
Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies. Int J Cancer (2003) 4.02
A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet (2010) 3.93
Multiple independent loci at chromosome 15q25.1 affect smoking quantity: a meta-analysis and comparison with lung cancer and COPD. PLoS Genet (2010) 3.91
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood (2006) 3.89
Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. PLoS One (2008) 3.87
Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet (2013) 3.81
Identification of a new prostate cancer susceptibility locus on chromosome 8q24. Nat Genet (2009) 3.76
Cancer risk prediction models: a workshop on development, evaluation, and application. J Natl Cancer Inst (2005) 3.75
Increased prevalence and mortality in undiagnosed celiac disease. Gastroenterology (2009) 3.73
False-positive results in cancer epidemiology: a plea for epistemological modesty. J Natl Cancer Inst (2008) 3.72
Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet (2012) 3.69
Detectable clonal mosaicism from birth to old age and its relationship to cancer. Nat Genet (2012) 3.68
Southern community cohort study: establishing a cohort to investigate health disparities. J Natl Med Assoc (2005) 3.67
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood (2007) 3.66
Genomic DNA hypomethylation as a biomarker for bladder cancer susceptibility in the Spanish Bladder Cancer Study: a case-control study. Lancet Oncol (2008) 3.60
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol (2006) 3.60
Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology (2003) 3.58
A shared susceptibility locus in PLCE1 at 10q23 for gastric adenocarcinoma and esophageal squamous cell carcinoma. Nat Genet (2010) 3.53